Go Pro
→ What Is A Roth Conversion, And How Do I Set One Up? (From SmartAsset) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Illumina, Inc. stock logo
ILMN
Illumina
$203.15
-0.9%		$200.29
$88.00
▼
$231.81
$30.63B1.461.89 million shs361,708 shs
Moderna, Inc. stock logo
MRNA
Moderna
$134.67
-0.7%		$89.93
$22.28
▼
$176.66
$53.75B1.111.57 million shs3.94 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Illumina, Inc. stock logo
ILMN
Illumina
-2.87%-3.87%+6.89%+23.34%+108.72%
Moderna, Inc. stock logo
MRNA
Moderna
-3.36%-10.08%+126.73%+173.19%+454.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Illumina, Inc. stock logo
ILMN
Illumina
$203.15
-0.9%		$200.29
$88.00
▼
$231.81
$30.63B1.461.89 million shs361,708 shs
Moderna, Inc. stock logo
MRNA
Moderna
$134.67
-0.7%		$89.93
$22.28
▼
$176.66
$53.75B1.111.57 million shs3.94 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Illumina, Inc. stock logo
ILMN
Illumina
-2.87%-3.87%+6.89%+23.34%+108.72%
Moderna, Inc. stock logo
MRNA
Moderna
-3.36%-10.08%+126.73%+173.19%+454.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Illumina, Inc. stock logo
ILMN
Illumina
2.44
Hold$199.13-1.98% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$76.72-43.03% Downside

Current Analyst Ratings Breakdown

Latest ILMN and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Illumina, Inc. stock logo
ILMN
Illumina
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral ➝ Buy$135.00 ➝ $260.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$81.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell
9/3/2026
Illumina, Inc. stock logo
ILMN
Illumina
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$180.00 ➝ $235.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$40.00 ➝ $81.00
9/1/2026
Illumina, Inc. stock logo
ILMN
Illumina
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/31/2026
Illumina, Inc. stock logo
ILMN
Illumina
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
Bradesco Corretora logo
Bradesco Corretora
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Illumina, Inc. stock logo
ILMN
Illumina
$4.34B7.06$6.46 per share31.43$17.82 per share11.40
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B27.66N/AN/A$22.14 per share6.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Illumina, Inc. stock logo
ILMN
Illumina
$850M$5.3637.8533.302.9918.36%29.84%12.17%10/29/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)

Latest ILMN and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/30/2026Q2 2026
Illumina, Inc. stock logo
ILMN
Illumina
$1.23$1.31+$0.08$1.35$1.13 billion$1.16 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Illumina, Inc. stock logo
ILMN
Illumina
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Illumina, Inc. stock logo
ILMN
Illumina
0.53
1.80
1.40
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18

Institutional Ownership

CompanyInstitutional Ownership
Illumina, Inc. stock logo
ILMN
Illumina
89.42%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Illumina, Inc. stock logo
ILMN
Illumina
2.90%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Illumina, Inc. stock logo
ILMN
Illumina
8,650151.00 million146.62 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable

Recent News About These Companies

Best Biotech Stocks To Add to Your Watchlist - September 10th
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-best-biotech-stocks-to-add-to-your-watchlist-september-10th-2026-09-10/
VIRGINIA RETIREMENT SYSTEMS ET Al Invests $4.44 Million in Moderna, Inc. $MRNA
September 10 at 5:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-virginia-retirement-systems-et-al-invests-444-million-in-moderna-inc-mrna-2026-09-10/
Moderna Set for 3 Near-Term INT Data Readouts, UBS Says
September 9 at 10:14 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/moderna-set-3-near-term-155826180.html
Biotech Stocks To Consider - September 9th
September 9 at 12:04 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-biotech-stocks-to-consider-september-9th-2026-09-09/
AI & Robotics in 2026: 16 Recent Developments for Investors
September 9 at 11:34 AM  |  etftrends.comE
Promising Biotech Stocks To Consider - September 7th
September 9 at 1:01 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31011657
What to know about the new mRNA flu vaccine
September 8 at 9:10 PM  |  hub.jhu.eduH
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?
September 8 at 11:41 AM  |  zacks.comhttps://www.zacks.com/stock/news/2986549/mrna-stock-soars-143-in-a-month-time-to-buy-hold-or-sell?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-2986549
MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?
September 8 at 11:09 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/mrna-stock-soars-143-month-144000490.html
Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’
September 8 at 6:09 AM  |  biospace.comB
Nykredit A S Invests $913,000 in Moderna, Inc. $MRNA
September 8 at 4:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nykredit-a-s-invests-913000-in-moderna-inc-mrna-2026-09-08/
Biotech Stocks Worth Watching - September 6th
September 8 at 1:02 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31009656
Moderna and Merck's custom mRNA cancer vaccines cut recurrence risk 50% in trials
September 6, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/moderna-and-mercks-custom-mrna-cancer-vaccines-cut-recurrence-risk-50-in-trials/vi-AA2bEHM7
After a rough stretch, mRNA gets a boost with cancer vaccines — for now
September 6, 2026  |  bostonglobe.comB
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
...
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/articles/moderna-just-doubled-overnight-and-2-more-healthcare-stocks-could-follow-it/
If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)
September 6, 2026  |  fool.comhttps://www.fool.com/investing/2026/09/06/if-youd-invested-in-moderna-mrna-stock-5-years-ago/
AlphaGrep UK Ltd Invests $568,000 in Moderna, Inc. $MRNA
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-alphagrep-uk-ltd-invests-568000-in-moderna-inc-mrna-2026-09-06/
Best Healthcare Stocks To Research - September 3rd
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31006086
Promising Biotech Stocks Worth Watching - September 5th
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/list-promising-biotech-stocks-worth-watching-september-5th-2026-09-05/
What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth?
September 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/does-moderna-mrna-bird-flu-041820711.html
Step Capital Management Pte. Ltd. Has $48.67 Million Stake in Moderna, Inc. $MRNA
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-step-capital-management-pte-ltd-has-4867-million-stake-in-moderna-inc-mrna-2026-09-05/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Moderna logo displayed in a laboratory setting with a vaccine vial, petri dishes, and a microscope.
Moderna’s 177% Surge Has Investors Asking What Comes Next
By Sam Quirke | August 21, 2026
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Illumina stock logo

Illumina NASDAQ:ILMN

$203.15 -1.85 (-0.90%)
As of 12:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$134.66 -0.95 (-0.70%)
As of 12:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas